Indeed, when subgroup analysis was performed on the Accord Lipid Study cohort, a highly significant CVD risk reduction of 31% was revealed in the fibrate-treated group [ 25 ].
← all excerpts
Revisiting cardiovascular risk reduction in type 2 diabetes and dyslipidemia.
1
—
—